Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18357107 | 1.00 | TSHR (0.41) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL13313896 | 0.94 | TSHR (0.37) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL18925943 | 0.92 | TSHR (0.36) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL18357023 | 0.84 | TSHR (0.39) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL13254408 | 0.84 | MEN1 (0.32) | — | |
| SCHEMBL24176568 | 0.82 | CHRNB2 (0.31) | — | |
| SCHEMBL15342848 | 0.82 | TSHR (0.42) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL195164 | 0.81 | HCAR2 (0.39) | TSHRCA1CA2ALDH1A1 | |
| SCHEMBL10011504 | 0.80 | TSHR (0.41) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL10011680 | 0.80 | TSHR (0.37) | TSHRCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238308-A1 | OLANZAPINE COMPOSITIONS AND METHODS OF USE | MEDINCELL S.A. (FR) | 2024-07-18 | — | — | US | disclosed |
| WO-2022003204-A1 | THERMOPLASTIC POLY(URETHANE-UREA) POLYADDUCTS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2022-01-06 | — | — | WO | disclosed |
| US-9472813-B2 | Battery electrolyte solution containing certain ester-based solvents, and batteries containing such an electrolyte solution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-10-18 | — | — | US | disclosed |
| CN-103262329-B | Battery electrolyte solution containing certain ester-based solvents and battery containing such electrolyte solution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-02-10 | — | — | CN | disclosed |
| EP-2652832-A1 | BATTERY ELECTROLYTE SOLUTION CONTAINING CERTAIN ESTER-BASED SOLVENTS, AND BATTERIES CONTAINING SUCH AN ELECTROLYTE SOLUTION | Dow Global Technologies LLC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130260229-A1 | BATTERY ELECTROLYTE SOLUTION CONTAINING CERTAIN ESTER-BASED SOLVENTS, AND BATTERIES CONTAINING SUCH AN ELECTROLYTE SOLUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-10-03 | — | — | US | disclosed |
| CN-103262329-A | Battery electrolyte solution containing certain ester-based solvents and battery containing such electrolyte solution | DOW GLOBAL TECHNOLOGIES INC | 2013-08-21 | — | — | CN | disclosed |
| WO-2012082760-A1 | BATTERY ELECTROLYTE SOLUTION CONTAINING CERTAIN ESTER-BASED SOLVENTS, AND BATTERIES CONTAINING SUCH AN ELECTROLYTE SOLUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-0972776-B1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | MITSUI CHEMICALS INC (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6153794-A | Phosphine sulfide, a manufacturing process therefor and use thereof | MITSUI CHEMICALS, INC. (JP) | 2000-11-28 | — | — | US | disclosed |
| CN-1262276-A | Phosphine sulfide preparing process and use thereof | MITSUI CHEMICALS INC (JP) | 2000-08-09 | — | — | CN | disclosed |
| EP-0972776-A1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | Mitsui Chemicals, Inc. (JP) | 2000-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238308-A1 | OLANZAPINE COMPOSITIONS AND METHODS OF USE | HTR2B, HTR1B, HTR3B | TSHR 645/4885CA12 3966/4885CA1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.